Institutional Repository of Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments | |
Du, Yang1,2; Liang, Xiaolong3; Li, Yuan1,4; Sun, Ting1,4; Xue, Huadan4; Jin, Zhengyu4; Tian, Jie1,2 | |
发表期刊 | CANCER LETTERS |
2018-02-01 | |
卷号 | 414期号:414页码:230-238 |
文章类型 | Article |
摘要 | Programmed death ligand-1 (PD-L1) is a central element in cancer therapies targeting immune checkpoints, and its expression is an important predictor of the therapeutic response. With recent approvals of therapeutic antibodies against PD-L1 and PD-1, noninvasive detection methods are now urgently needed to quantify PD-L1 expression in tumors and to evaluate the response to immune therapies. However, only few such methods are available. Thus, we fabricated nanohybrid liposomal cerasome nanoparticles loaded with the chemotherapeutic drug paclitaxel, and evaluated their value as a theranostic agent. The particles are also decorated with PD-L1 antibody to enable specific targeting, and are dual-labeled to enable near-infrared fluorescence (NIRF) and magnetic resonance imaging (MRI) in vivo. Results showed that in vivo NIRF and MRI imaging following intravenous injection of cerasomes revealed a strong positive contrast for tumors, indicating long-lived enhancement of relevant signals. Moreover, the cerasomes were more effective against tumors and metastasis in comparison to simultaneous but nontargeted delivery of PD-L1 antibody and paclitaxel. Taken together, the data indicate that targeted, dual-labeled cerasomes are good theranostic agents for MRI/NIRF dual-mode detection and treatment of solid tumors in situ. (C) 2017 Elsevier B.V. All rights reserved. |
关键词 | Programmed Cell Death Ligand-1 Near Infrared Fluorescence Magnetic Resonance Imaging Paclitaxel Chemotherapy Immunotherapy |
WOS标题词 | Science & Technology ; Life Sciences & Biomedicine |
DOI | 10.1016/j.canlet.2017.11.019 |
关键词[WOS] | IMMUNE CHECKPOINT BLOCKADE ; CELL LUNG-CANCER ; THERAPY ; IMMUNOTHERAPY ; CHEMOTHERAPY ; TUMORS ; NANOPARTICLES ; COMBINATION ; EXPRESSION ; STABILITY |
收录类别 | SCI |
语种 | 英语 |
项目资助者 | National Natural Science Foundation of China(81227901 ; Research and Development Program of China (973)(2014CB748600 ; National Key Research and Development Program of China(2017YFA0205200) ; Chinese Academy of Sciences(XDB02060010) ; International Innovation Team of CAS(20140491524) ; Beijing Municipal Science & Technology Commission(Z161100002616022) ; Beijing Natural Science Foundation(Z16110200010000) ; Peking University Third Hospital(BYSY2015023) ; 81470083 ; 2015CB755500) ; 81527805 ; 61231004 ; 81571810 ; 81771846) |
WOS研究方向 | Oncology |
WOS类目 | Oncology |
WOS记录号 | WOS:000419810900024 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.ia.ac.cn/handle/173211/19586 |
专题 | 中国科学院分子影像重点实验室 |
作者单位 | 1.Chinese Acad Sci, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Inst Automat, Beijing 100190, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100080, Peoples R China 3.Peking Univ, Hosp 3, Dept Ultrasound, Beijing 100191, Peoples R China 4.Beijing Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China |
推荐引用方式 GB/T 7714 | Du, Yang,Liang, Xiaolong,Li, Yuan,et al. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments[J]. CANCER LETTERS,2018,414(414):230-238. |
APA | Du, Yang.,Liang, Xiaolong.,Li, Yuan.,Sun, Ting.,Xue, Huadan.,...&Tian, Jie.(2018).Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.CANCER LETTERS,414(414),230-238. |
MLA | Du, Yang,et al."Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments".CANCER LETTERS 414.414(2018):230-238. |
条目包含的文件 | 下载所有文件 | |||||
文件名称/大小 | 文献类型 | 版本类型 | 开放类型 | 使用许可 | ||
Cancer letter-du.pdf(3002KB) | 期刊论文 | 作者接受稿 | 开放获取 | CC BY-NC-SA | 浏览 下载 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论